Replies to post #201943 on Biotech Values

[DewDiligence]

Any views on ICPT if suitable for a bigger suitor in this current stage?

If I were shopping for a biotech company with my own money, I would pass on ICPT. The phase-3 REGENERATE trial is laden with pitfalls, IMO (#msg-117301781), and a monotherapy is unlikely to be the answer in a multifaceted disease such as NASH.